Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 18, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Rheumatoid factor interference in a tacrolimus immunoassay.

Bernardí Barceló Martín1, Pierre Marquet, Joana Maria Ferrer

  • 1Servei d'Anàlisis Clíniques, Hospital Son Dureta, Palma de Mallorca, Spain. bernardino.barcelo@ssib.es

Therapeutic Drug Monitoring
|November 26, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy.

Antimicrobial agents and chemotherapy·2026
Same author

Causal inference and digital twins: a roadmap for the future of clinical trials.

NPJ digital medicine·2026
Same author

Human serum albumin profiling by top-down analysis enables multi-class liver fibrosis staging: a cross-platform validation study.

Scientific reports·2026
Same author

Monte Carlo simulations identify suboptimal PK/PD target attainment with standard maribavir dosing.

The Journal of antimicrobial chemotherapy·2026
Same author

Intragraft clonal expansion of cytotoxic CD8<sup>+</sup> and CD4<sup>+</sup> T cells in antibody-mediated kidney transplant rejection.

Kidney international·2026
Same author

CNI Trough Variability Does Not Reliably Reflect Medication Adherence: Insights From a 3-Year Follow-Up Study.

Transplant international : official journal of the European Society for Organ Transplantation·2026

Rheumatoid factor (RF) can cause false-positive tacrolimus results in specific immunoassays used for rheumatoid arthritis (RA) monitoring. Pre-treating samples with an immunoglobulin blocking agent resolved these interferences.

Area of Science:

  • Clinical Chemistry
  • Immunology
  • Pharmacology

Background:

  • Tacrolimus is being investigated for rheumatoid arthritis (RA) treatment.
  • Rheumatoid factor (RF) is a known cause of immunoassay interference.
  • The impact of RF on tacrolimus immunoassays is not well-documented.

Purpose of the Study:

  • To investigate the susceptibility of a specific tacrolimus immunoassay to RF interference.
  • To determine if RF in RA patients leads to inaccurate tacrolimus measurements.
  • To assess the effectiveness of blocking agents in mitigating potential interferences.

Main Methods:

  • Analyzed 100 RA patient samples (50 with high RF, 50 with low RF) for tacrolimus using antibody conjugated magnetic immunoassay (ACMIA) on a Dimension RxL system.

Related Experiment Videos

Last Updated: Jun 18, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

  • Identified potential false positives based on a threshold of 2.3 ng/mL.
  • Treated positive samples with an immunoglobulin blocking agent and re-tested using ACMIA and alternative assays.

    • Main Results:

    • No false positives were observed in samples with low RF (< 20 IU/mL).
    • Two samples with high RF (> 100 IU/mL) showed false-positive tacrolimus results by ACMIA.
    • Interference was eliminated after treatment with a blocking agent and confirmed by alternative assays, with elevated human anti-mouse antibodies noted.

    Conclusions:

    • The tacrolimus ACMIA-Flex immunoassay on the Dimension RXL analyzer can yield false-positive results in patients with positive RF.
    • Interference is linked to RF and potentially human anti-mouse antibodies.
    • Immunoglobulin blocking agents can successfully mitigate RF interference in tacrolimus ACMIA testing.